Monkeypox/smallpox vaccine approved by FDA

On September 24, 2019, the FDA approved the first live, non-replicating vaccine called Jynneos, to prevent smallpox and monkeypox. Jynneos contains a modified form of the vaccinia virus called “Modified Vaccinia Ankara”.  The vaccine will be part of the Strategic National Stockpile (SNS). [4]

Dr Rick Bright [1, 2, 3] from BARDA, wrote on the HHS blog that this “newly licensed vaccine resulted from years of dedication and collaboration between the private sector and the U.S. government”…because “the virus remains a potential global security threat.”

“Monkeypox, which does not occur naturally in the U.S., is a rare disease caused by infection with monkeypox virus, which causes symptoms similar to, but milder than, smallpox.”

More on monkeypox – HERE